Probing the unknown in cancer of unknown primary: Which way is the right way?
dc.contributor.author | Pentheroudakis, George | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Pentheroudakis, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:54:25Z | |
dc.date.available | 2018-06-22T09:54:25Z | |
dc.date.issued | 2010 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42350 | |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Humans | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Cancer survival | en |
dc.subject | Carboplatin | en |
dc.subject | Neoplasm staging | en |
dc.subject | Paclitaxel | en |
dc.subject | Priority journal | en |
dc.subject | Prognosis | en |
dc.subject | Retrospective studies | en |
dc.subject | Retrospective study | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical trial | en |
dc.subject | Gemcitabine | en |
dc.subject | Taxane derivative | en |
dc.subject | Survival analysis | en |
dc.subject | Cancer staging | en |
dc.subject | Survival | en |
dc.subject | Metastasis | en |
dc.subject | Cancer mortality | en |
dc.subject | Bone metastasis | en |
dc.subject | Platinum complex | en |
dc.subject | Mortality | en |
dc.subject | Risk assessment | en |
dc.subject | Axillary lymph node | en |
dc.subject | Histopathology | en |
dc.subject | Survival time | en |
dc.subject | Procedures | en |
dc.subject | Colon cancer | en |
dc.subject | Prostate cancer | en |
dc.subject | Pathology | en |
dc.subject | Bevacizumab | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Squamous cell carcinoma | en |
dc.subject | Cancer of unknown primary site | en |
dc.subject | Unknown primary | en |
dc.subject | Cancer localization | en |
dc.subject | Cohort analysis | en |
dc.subject | Cancer palliative therapy | en |
dc.subject | Neuroendocrine tumor | en |
dc.subject | Editorial | en |
dc.subject | Carcinomatous peritonitis | en |
dc.subject | Cancer resistance | en |
dc.subject | Epidermal growth factor receptor kinase inhibitor | en |
dc.subject | Cohort studies | en |
dc.subject | Soft tissue metastasis | en |
dc.subject | Inguinal lymph node | en |
dc.subject | Cancer control | en |
dc.subject | Cervical lymphadenopathy | en |
dc.subject | Drug delivery system | en |
dc.subject | Drug delivery systems | en |
dc.subject | Viscera | en |
dc.title | Probing the unknown in cancer of unknown primary: Which way is the right way? | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/annonc/mdp609 | |
dc.description.volume | 21 | |
dc.description.issue | 6 | |
dc.description.startingpage | 1143 | |
dc.description.endingpage | 1144 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |